anticoagulant, curative dose - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.06 [0.83, 1.37]< 139%3 studies (3/-)31.5 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.35 [0.85, 2.15]< 10%1 study (1/-)10.4 %NAnot evaluable important-
clinical improvement 0.83 [0.67, 1.03]> 10%1 study (1/-)4.5 %NAnot evaluable important-
clinical improvement (28-day) 1.27 [1.03, 1.57]> 10%1 study (1/-)98.6 %NAnot evaluable important-
death or ventilation 0.82 [0.63, 1.07]< 10%1 study (1/-)92.9 %NAnot evaluable important-
Major thrombotic events or death 1.04 [0.80, 1.36]< 10%1 study (1/-)38.7 %NAnot evaluable non important-

safety endpoints 00

Major bleeding 1.74 [1.10, 2.75]< 10%3 studies (3/-)0.9 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 0.73 [0.41, 1.29]< 10%1 study (1/-)85.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.